LGALS3 and central nervous system cancer: In 2001 Strik et al. tried to clarify this issue and studied cellular and regional distribution of galectin-3 and compared it with immunoreactivity to the macrophage marker CD68 in 53 gliomas (WHO-grades II–IV) by immunohistochemistry.